Insulet
Acton, Massachusetts, United States · Biotechnology, Health Care, Medical
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is a medical device company simplifying life for people with diabetes through its Omnipod product platform. The tubeless, wearable Pod delivers up to three days of insulin without injections or fingersticks, with the Omnipod 5 system integrating with continuous glucose monitoring and smartphone control. Beyond diabetes, Insulet is
Key facts
- Headquarters
- Acton, Massachusetts, United States
- Employees
- 3,900
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (PODD)
- Website
- insulet.com
- Company page
Recent activity at Insulet
- : SEC 8-K (7.01): On October 30, 2026, Insulet Corporation's Board of Directors authorized a stock repurchase program that allows the Company to buy back up to $1 billion of its common stock through December 31, 2028. The Company plans to use approximately $400 million of this program for repurchases in the fourth quarter of 2026, funded by existing cash. The repurchasing may be conducted via various methods, including open market purchases and privately negotiated transactions, and the program's execution will depend on market conditions and legal requirements. This decision adds to prior authorizations and is not obligatory, meaning the Company has the flexibility to extend or modify the program at any time.
- : SEC 8-K (1.01): On September 21, 2026, Insulet Corporation entered into the Ninth Amendment to its Credit Agreement with lenders and Morgan Stanley Senior Funding, Inc. as the administrative agent. This amendment replaced $475 million of existing term loans with new term loans having similar terms but a lower interest rate margin of 0.75% for base rate loans and 1.75% for term SOFR loans. Additionally, revolving credit commitments were increased by $250 million, bringing the total to $750 million, with reduced interest rates, thus enhancing the company's financial flexibility. These actions were taken to refinance existing debt and better position the company for working capital and general corporate needs.
- : SEC 8-K (5.02): On September 14, 2026, Insulet Corporation's Talent and Compensation Committee approved the Insulet Nonqualified Deferred Compensation Plan, which will be effective January 1, 2027. This plan is designed as an unfunded 'top hat' deferred compensation plan that allows select management or highly compensated employees to voluntarily defer their compensation in accordance with Section 409A of the Internal Revenue Code. This action is part of the Company's strategic approach to retain and incentivize key executive talent, specifically targeting the company's named executive officers and other top employees. By facilitating deferred compensation, the Company aims to provide flexible retirement options for its executives.
- : SEC 8-K (5.02):
- : Insulet partners with Calm to develop mindfulness content for diabetes management.
- : Insulet Partners With Calm to Provide Mental Health Support for Diabetes Management.
- : SEC 8-K (5.02): On June 24, 2026, Insulet Corporation appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky, previously the Executive Chair of IDEXX Laboratories, has extensive leadership experience, having served in various executive roles within the healthcare sector. As a non-employee director, he will receive an initial grant of restricted stock units valued at $216,548, based on a pro-rated annual award of $260,000. This appointment is strategic for Insulet as it seeks to leverage Mr. Mazelsky's deep industry experience in its future endeavors. Additionally, the Company announced this appointment through a press release on June 25, 2026, detailing his extensive background and the compensation arrangements.
- : Insulet Corporation Appoints Mike Panos as Chief Commercial Officer
- : SEC 8-K (7.01): On May 26, 2026, Insulet Corporation issued a Regulation FD Disclosure regarding a voluntary Medical Device Correction for specific lots of its Omnipod® products due to a manufacturing issue identified through product monitoring. This action pertains to approximately 7 million Pods, with about 60% already consumed or expired. The Company anticipates costs of up to $50 million associated with this correction in 2026, but does not expect any disruption to customer shipments or product availability and is maintaining its 2026 guidance. The disclosure highlights corrective actions taken to address cannula handling issues identified at their Acton, Massachusetts facility, separate from a previous March 2026 correction.
- : SEC 8-K (5.03): On May 20, 2026, Insulet Corporation's Board of Directors approved an amendment and restatement of the Company’s Bylaws, designating specific courts as the exclusive forum for certain legal actions including derivative actions and breaches of fiduciary duty. The changes were implemented immediately and specify that the Court of Chancery of the State of Delaware will be the primary venue, with fallback options if it lacks jurisdiction. This amendment could streamline legal processes and potentially reduce litigation costs for the company, signaling a strategic move to improve governance and clarity in legal proceedings.
Leadership
- Mike Panos, Chief Commercial Officer
- Ana M. Chadwick, Chief Financial Officer
- Jen Kramer, Owner and Chief Instructional Designer
- Flavia Pease, Chief Financial Officer
- Manoj Raghunandanan, Chief Growth Officer
- Eric Benjamin, Chief Operating Officer
- Ashley McEvoy, President
Verified email and direct lines for Insulet’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Insulet files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Insulet in the news
- Insulet Announces Omnipod Discover Now Available in U.S. - Business Wire (Oct 12, 2026)
- Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom - Insulet Corporation - Investor Relations (Jun 20, 2023)
- Insulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New Palette - Insulet Corporation - Investor Relations (Sep 18, 2025)
- Clinical Overview: Omnipod 5 Automated Tubeless Insulin Dispensing System - Pharmacy Times (Mar 22, 2022)
- Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes - Insulet Corporation - Investor Relations (Apr 25, 2023)
- Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care - Business Wire (Jun 06, 2026)
- Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod - Business Wire (May 26, 2026)
- Omnipod® Insulin Management System Now the Preferred Insulin Pump in British Columbia, Canada - Insulet Corporation - Investor Relations (Jul 03, 2018)
Companies similar to Insulet
- Esaote Group · Biotechnology, Health Care, Medical, Medical Device, medical devices
- InMode · Biotechnology, Health Care, Medical, Medical Device, medical devices
- Avania · Biotechnology, Health Care, Medical, Medical Device, medical devices
- Zimmer · Biotechnology, Health Care, Medical, Medical Device, medical devices
- Mindray · Biotechnology, Health Care, Medical, Medical Device, medical devices
About Insulet: questions and answers
What does Insulet do?
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is a medical device company simplifying life for people with diabetes through its Omnipod product platform. The tubeless, wearable Pod delivers up to three days of insulin without injections or fingersticks, with the Omnipod 5 system integrating with continuous glucose monitoring and smartphone control. Beyond diabetes, Insulet is
Where is Insulet headquartered?
Insulet is headquartered in Acton, Massachusetts, United States.
How many employees does Insulet have?
Insulet has about 3,900 employees.
Who leads Insulet?
Ashley McEvoy is a President at Insulet.
What is the latest news on Insulet?
On Nov 04, 2026, SEC 8-K (7.01): On October 30, 2026, Insulet Corporation's Board of Directors authorized a stock repurchase program that allows the Company to buy back up to $1 billion of its common stock through December 31, 2028. The Company plans to use approximately $400 million of this program for repurchases
Is Insulet a public company?
Yes. Insulet is publicly traded under the ticker PODD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy